Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data - Poll - MDSpire

Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data

  • By

  • Li Lin

  • Maohua Chen

  • Chenmin Wu

  • Hong Chen

  • July 10, 2026

  • 0 min

Share

Original Source(s)

Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data

  • by Li Lin, Maohua Chen, Chenmin Wu, Hong Chen

  • July 10, 2026

Related Content

CD19, immunoglobulin level, and varied anti-cytokine autoantibodies underline dichotomous susceptibility to types of infection in patients with thymomas

Fibroblast activation protein inhibitor radiotheranostics for imaging activated tumor stroma and guiding radionuclide therapy

Nutritional interventions in cancer management: a comprehensive scoping review